Cargando…
Xanthine–Dopamine Hybrid Molecules as Multitarget Drugs with Potential for the Treatment of Neurodegenerative Diseases
Multitarget drugs based on a hybrid dopamine–xanthine core were designed as potential drug candidates for the treatment of neurodegenerative diseases. Monoamine oxidase B (MAO-B) inhibitors with significant ancillary A(2A) adenosine receptor (A(2A)AR) antagonistic properties were further developed t...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377586/ https://www.ncbi.nlm.nih.gov/pubmed/37509114 http://dx.doi.org/10.3390/biom13071079 |
_version_ | 1785079554234122240 |
---|---|
author | Załuski, Michał Karcz, Tadeusz Drabczyńska, Anna Vielmuth, Christin Olejarz-Maciej, Agnieszka Głuch-Lutwin, Monika Mordyl, Barbara Siwek, Agata Satała, Grzegorz Müller, Christa E. Kieć-Kononowicz, Katarzyna |
author_facet | Załuski, Michał Karcz, Tadeusz Drabczyńska, Anna Vielmuth, Christin Olejarz-Maciej, Agnieszka Głuch-Lutwin, Monika Mordyl, Barbara Siwek, Agata Satała, Grzegorz Müller, Christa E. Kieć-Kononowicz, Katarzyna |
author_sort | Załuski, Michał |
collection | PubMed |
description | Multitarget drugs based on a hybrid dopamine–xanthine core were designed as potential drug candidates for the treatment of neurodegenerative diseases. Monoamine oxidase B (MAO-B) inhibitors with significant ancillary A(2A) adenosine receptor (A(2A)AR) antagonistic properties were further developed to exhibit additional phosphodiesterase-4 and -10 (PDE4/10) inhibition and/or dopamine D(2) receptor (D(2)R) agonistic activity. While all of the designed compounds showed MAO-B inhibition in the nanomolar range mostly combined with submicromolar A(2A)AR affinity, significant enhancement of PDE-inhibitory and D(2)R-agonistic activity was additionally reached for some compounds through various structural modifications. The final multitarget drugs also showed promising antioxidant properties in vitro. In order to evaluate their potential neuroprotective effect, representative ligands were tested in a cellular model of toxin-induced neurotoxicity. As a result, protective effects against oxidative stress in neuroblastoma cells were observed, confirming the utility of the applied strategy. Further evaluation of the newly developed multitarget ligands in preclinical models of Alzheimer’s and Parkinson’s diseases is warranted. |
format | Online Article Text |
id | pubmed-10377586 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103775862023-07-29 Xanthine–Dopamine Hybrid Molecules as Multitarget Drugs with Potential for the Treatment of Neurodegenerative Diseases Załuski, Michał Karcz, Tadeusz Drabczyńska, Anna Vielmuth, Christin Olejarz-Maciej, Agnieszka Głuch-Lutwin, Monika Mordyl, Barbara Siwek, Agata Satała, Grzegorz Müller, Christa E. Kieć-Kononowicz, Katarzyna Biomolecules Article Multitarget drugs based on a hybrid dopamine–xanthine core were designed as potential drug candidates for the treatment of neurodegenerative diseases. Monoamine oxidase B (MAO-B) inhibitors with significant ancillary A(2A) adenosine receptor (A(2A)AR) antagonistic properties were further developed to exhibit additional phosphodiesterase-4 and -10 (PDE4/10) inhibition and/or dopamine D(2) receptor (D(2)R) agonistic activity. While all of the designed compounds showed MAO-B inhibition in the nanomolar range mostly combined with submicromolar A(2A)AR affinity, significant enhancement of PDE-inhibitory and D(2)R-agonistic activity was additionally reached for some compounds through various structural modifications. The final multitarget drugs also showed promising antioxidant properties in vitro. In order to evaluate their potential neuroprotective effect, representative ligands were tested in a cellular model of toxin-induced neurotoxicity. As a result, protective effects against oxidative stress in neuroblastoma cells were observed, confirming the utility of the applied strategy. Further evaluation of the newly developed multitarget ligands in preclinical models of Alzheimer’s and Parkinson’s diseases is warranted. MDPI 2023-07-05 /pmc/articles/PMC10377586/ /pubmed/37509114 http://dx.doi.org/10.3390/biom13071079 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Załuski, Michał Karcz, Tadeusz Drabczyńska, Anna Vielmuth, Christin Olejarz-Maciej, Agnieszka Głuch-Lutwin, Monika Mordyl, Barbara Siwek, Agata Satała, Grzegorz Müller, Christa E. Kieć-Kononowicz, Katarzyna Xanthine–Dopamine Hybrid Molecules as Multitarget Drugs with Potential for the Treatment of Neurodegenerative Diseases |
title | Xanthine–Dopamine Hybrid Molecules as Multitarget Drugs with Potential for the Treatment of Neurodegenerative Diseases |
title_full | Xanthine–Dopamine Hybrid Molecules as Multitarget Drugs with Potential for the Treatment of Neurodegenerative Diseases |
title_fullStr | Xanthine–Dopamine Hybrid Molecules as Multitarget Drugs with Potential for the Treatment of Neurodegenerative Diseases |
title_full_unstemmed | Xanthine–Dopamine Hybrid Molecules as Multitarget Drugs with Potential for the Treatment of Neurodegenerative Diseases |
title_short | Xanthine–Dopamine Hybrid Molecules as Multitarget Drugs with Potential for the Treatment of Neurodegenerative Diseases |
title_sort | xanthine–dopamine hybrid molecules as multitarget drugs with potential for the treatment of neurodegenerative diseases |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377586/ https://www.ncbi.nlm.nih.gov/pubmed/37509114 http://dx.doi.org/10.3390/biom13071079 |
work_keys_str_mv | AT załuskimichał xanthinedopaminehybridmoleculesasmultitargetdrugswithpotentialforthetreatmentofneurodegenerativediseases AT karcztadeusz xanthinedopaminehybridmoleculesasmultitargetdrugswithpotentialforthetreatmentofneurodegenerativediseases AT drabczynskaanna xanthinedopaminehybridmoleculesasmultitargetdrugswithpotentialforthetreatmentofneurodegenerativediseases AT vielmuthchristin xanthinedopaminehybridmoleculesasmultitargetdrugswithpotentialforthetreatmentofneurodegenerativediseases AT olejarzmaciejagnieszka xanthinedopaminehybridmoleculesasmultitargetdrugswithpotentialforthetreatmentofneurodegenerativediseases AT głuchlutwinmonika xanthinedopaminehybridmoleculesasmultitargetdrugswithpotentialforthetreatmentofneurodegenerativediseases AT mordylbarbara xanthinedopaminehybridmoleculesasmultitargetdrugswithpotentialforthetreatmentofneurodegenerativediseases AT siwekagata xanthinedopaminehybridmoleculesasmultitargetdrugswithpotentialforthetreatmentofneurodegenerativediseases AT satałagrzegorz xanthinedopaminehybridmoleculesasmultitargetdrugswithpotentialforthetreatmentofneurodegenerativediseases AT mullerchristae xanthinedopaminehybridmoleculesasmultitargetdrugswithpotentialforthetreatmentofneurodegenerativediseases AT kieckononowiczkatarzyna xanthinedopaminehybridmoleculesasmultitargetdrugswithpotentialforthetreatmentofneurodegenerativediseases |